Get the Stockscreener App
2.8326
0.96%
-0.0274
Neuraxis Inc stock is traded at $2.8326, with a volume of 9,173.
It is down -0.96% in the last 24 hours and up +19.52% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.86
Open:
$2.8568
24h Volume:
9,173
Relative Volume:
0.01
Market Cap:
$20.55M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.5118
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+19.52%
1M Performance:
+19.52%
6M Performance:
-6.21%
1Y Performance:
-9.21%
1-Day Range:
$2.8125
$2.8901
1-Week Range:
$2.42
$2.92
52-Week Range:
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.8473 | 23.44M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.00 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.62 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.60 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.93 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Stock (NRXS) Latest News
Is NeurAxis Inc. a good long term investmentSky-high profits - jammulinksnews.com
What drives NeurAxis Inc. stock priceConsistent high-yield stocks - jammulinksnews.com
NeurAxis Inc. Stock Analysis and ForecastAccelerated profit realization - jammulinksnews.com
What analysts say about NeurAxis Inc. stockFast-track wealth growth - jammulinksnews.com
is neuraxis inc. stock a growth or value play2x 3x 5x Pick Alert - Newser
Why NeurAxis Inc. stock is on top investor watchlistsMinimized Risk Maximum Return - Newser
Is NeurAxis Inc. stock a growth or value playFree Signals Group - Newser
Published on: 2025-07-18 00:27:06 - Newser
How NeurAxis Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser
Why NeurAxis Inc. stock attracts strong analyst attentionGrowth Optimized Stock Radar - Newser
What makes NeurAxis Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Thursday’s Insider Moves: Top Executives Make Strategic Trades - Investing.com Australia
Major Shareholder Sells Massive Stake in NeurAxis, Inc. - TipRanks
Neuraxis ends Masimo license agreement and launches employee stock plan - Investing.com
Neuraxis Inc: Brian Hannasch buys $800k in shares - Investing.com
Neuraxis Inc: Brian Hannasch buys $800k in shares By Investing.com - Investing.com Nigeria
The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technologies and NeurAxis - Yahoo Finance
Top Stock Reports for Microsoft, NVIDIA & Bank of America - TradingView
Neuraxis announces new medical policy with two health insurers - TipRanks
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - GlobeNewswire
NeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal Pain - Nasdaq
NeurAxis (NASDAQ:NRXS) Now Covered by Analysts at Craig Hallum - Defense World
Neuraxis (NRXS) Initiated with Buy Rating by Craig-Hallum | NRXS Stock News - GuruFocus
Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device - Investing.com India
Craig-Hallum bullish on Neuraxis, initiates with a Buy - TipRanks
Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain in Ibs - MarketScreener
NeurAxis (NRXS) Gains Momentum with Key Guideline Inclusion | NR - GuruFocus
Neuraxis secures key academic society guidelines recommendation for FAP - TipRanks
NeurAxis Achieves Critical Milestone; Secures Key Academic - GlobeNewswire
Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option - Stock Titan
47,094 Shares in NeurAxis, Inc. (NASDAQ:NRXS) Bought by Citadel Advisors LLC - Defense World
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.20%
0.52%
Cap:
|
Volume (24h):